Overview of Voting Rights and Share Capital
In the financial landscape, understanding voting rights and share capital is crucial for investors and stakeholders alike. This information helps clarify the governance of a company and influences investment decisions. With Nanobiotix at the forefront of biotechnology, the implications of their share capital and voting rights are significant within the healthcare sector.
Current Shareholder Information
As of the latest reporting period, the number of shares outstanding for Nanobiotix stands at 47,426,851. The total number of theoretical voting rights is calculated at 49,201,086, while the exercisable voting rights amount to 49,178,968. This data is pivotal for shareholders looking to understand their influence in company decisions.
Importance of Voting Rights
Voting rights allow shareholders to participate in important company decisions, such as electing the board of directors or approving mergers and acquisitions. This involvement is a key aspect of corporate governance, ensuring that the interests of all shareholders are represented. Nanobiotix, with its robust platform in groundbreaking cancer treatments, aims to ensure that its shareholders are informed and engaged in the decision-making process.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company dedicated to revolutionizing cancer treatment. Founded in 2003 and headquartered in Paris, France, the organization is committed to pushing beyond the limits of conventional therapeutic approaches. Since its inception, Nanobiotix has been successful in developing innovative solutions that focus on several therapeutic areas including oncology, enhancing bioavailability, and addressing central nervous system disorders.
Innovation and Patents
The company boasts ownership of over 25 patent families stemming from three main nanotechnology platforms. This impressive portfolio not only showcases the commitment to research and development but also highlights the potential impact their technology can have on patient outcomes globally. Investing in Nanobiotix represents an opportunity to be part of a vision that aims to provide groundbreaking solutions in healthcare.
Investor Relations and Communications
For those interested in exploring more about Nanobiotix, the company actively engages with its investors and the media through strategic communication channels. The Investor Relations Department, led by the SVP Craig West, can be reached with inquiries about investments and shareholder concerns. This communication is crucial for maintaining transparency and fostering trust amongst its investors.
Contact Information
The Communications Department, represented by Brandon Owens, is here to assist with any media-related questions. Users can contact either department for information. This accessibility reflects the company's commitment to maintaining a strong relationship with all stakeholders.
Frequently Asked Questions
What are the latest voting rights figures for NANOBIOTIX?
The latest figures indicate that NANOBIOTIX has 47,426,851 shares outstanding, with 49,201,086 theoretical voting rights and 49,178,968 exercisable voting rights.
How does voting influence decisions at NANOBIOTIX?
Voting rights empower shareholders to participate in key decisions like board elections and strategic shifts, ensuring their interests are voiced.
When was NANOBIOTIX established?
NANOBIOTIX was founded in 2003 and has since evolved into a pivotal player in the biotechnology sector.
What is unique about NANOBIOTIX’s technology?
The company utilizes innovative nanotechnology platforms to develop treatments aimed at revolutionizing cancer therapy and enhancing drug delivery systems.
Who are the main contacts for investor communications at NANOBIOTIX?
The main contacts are Brandon Owens for communications and Craig West for investor relations, both of whom are readily available for inquiries.
